US · 21 CFR
21 CFR Part 4
Regulation of Combination Products
eCFR, up to date as of 2026-11-12
조항 목차
- 4.1What is the scope of this subpart?
- 4.2How does FDA define key terms and phrases in this subpart?
- 4.3What current good manufacturing practice requirements apply to my combination product?
- 4.4How can I comply with these current good manufacturing practice requirements for a co-packaged or single-entity combination product?
- 4.100What is the scope of this subpart?
- 4.101How does the FDA define key terms and phrases in this subpart?
- 4.102What reports must you submit to FDA for your combination product or constituent part?
- 4.103What information must you share with other constituent part applicants for the combination product?
- 4.104How and where must you submit postmarketing safety reports for your combination product or constituent part?
- 4.105What are the postmarketing safety reporting recordkeeping requirements for your combination product or constituent part?
표지·목차 원문
Authority:21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360b-360f, 360h-360j, 360l, 360hh-360ss, 360aaa-360bbb, 360ddd, 360ddd-1, 371(a), 372-374, 379e, 381, 383, 394; 42 U.S.C. 216, 262, 263a, 264, 271.
Source:78 FR 4321, Jan. 22, 2013, unless otherwise noted.
출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16